# Effect of short-term intensive insulin pump therapy on serum endotrophin levels in patients with newly diagnosed type 2 diabetes

## TL;DR

Short-term intensive insulin pump therapy lowers serum endotrophin levels in newly diagnosed type 2 diabetes patients, which are linked to insulin resistance.

## Contribution

This study is the first to show that STII pump therapy reduces endotrophin levels and its association with improved insulin resistance in type 2 diabetes.

## Key findings

- Patients with type 2 diabetes had higher serum endotrophin levels than healthy controls.
- Two weeks of STII pump therapy significantly reduced serum endotrophin levels in type 2 diabetes patients.
- Endotrophin levels correlated with insulin resistance both before and after treatment.

## Abstract

To investigate the effect of short-term intensive insulin (STII) pump therapy on serum endotrophin (ETP) levels in patients with newly diagnosed type 2 diabetes, examine the relationship between serum ETP levels and insulin resistance (IR).

Our study recruited 40 patients with newly diagnosed type 2 diabetes and 40 healthy controls. First, we compared the serum ETP levels between patients with newly diagnosed type 2 diabetes and controls. Second, 40 patients with newly diagnosed type 2 diabetes underwent two weeks of STII pump therapy.

Higher serum ETP levels were observed in patients with newly diagnosed type 2 diabetes compared to controls. After 2 weeks of STII pump therapy, serum ETP levels significantly attenuated in patients with newly diagnosed type 2 diabetes. Both before and after treatment, serum ETP exhibited a significant positive correlation with homeostasis model 2 assessment of IR (HOMA2-IR). Multiple linear regression analysis revealed that changes in ETP levels (δ-ETP) were independently associated with changes in HOMA2-IR (δ-HOMA2-IR).

Serum ETP serves as a risk factor for type 2 diabetes and correlates with insulin resistance index. STII contributed to reducing the heightened inflammatory response in individuals with type 2 diabetes.